Regulation of B Cell Functions by C3a and C3adesArg: Suppression of TNF-α, IL-6, and the Polyclonal Immune Response

Journal of Immunology

Volumn 159, Issue 9, 1997, Pages 4279-4286

  Fischer, Wolfgang H ^a   Hugli, Tony E ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPHYLATOXIN; COMPLEMENT C3A RECEPTOR; COMPLEMENT C3A, DES ARG (77); COMPLEMENT C3A, DES-ARG-(77); COMPLEMENT COMPONENT C3A; COMPLEMENT RECEPTOR; DRUG DERIVATIVE; INTERLEUKIN 6; MEMBRANE PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ANIMAL; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; BIOSYNTHESIS; CELL CULTURE; CHILD; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MOUSE; PRESCHOOL CHILD; STAPHYLOCOCCUS AUREUS;

ADOLESCENT; ANAPHYLATOXINS; ANIMALS; ANTIBODY FORMATION; B-LYMPHOCYTES; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; COMPLEMENT C3A; HUMANS; INTERLEUKIN-6; MEMBRANE PROTEINS; MICE; RECEPTORS, COMPLEMENT; STAPHYLOCOCCUS AUREUS; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031280069     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Law, S. K., and K. M. Reid. 1995. Activation and control of the complement system. In Focus: Complement. D. Male, ed. Oxford University Press, New York, p. 11.
2. Weinberg, P. F., M. A. Matthay, O. Webster, K. V. Roskos, I. M. Goldstein, and J. F. Murray. 1984. Biologically active products of complement and acute lung injury in patients with sepsis syndrome. Am. Rev. Respir. Dis. 130:791.
3. Bengston, A., and M. Heideman. 1988. Anaphylatoxin formation in sepsis. Arch. Surg. 123:645.
4. Heideman, M., and T. E. Hugli. 1984. Anaphylatoxin generation in multisystem organ failure. J. Trauma 24:1038.
5. Zilow, G., T. Joka, U. Obertacke, U. Rother, and M. Kirschfink. 1992. Generation of anaphylatoxin C3a in plasma and bronchoalveolar lavage fluid in trauma patients at risk for adult respiratory distress syndrome. Crit. Care Med. 20:468.
6. Belmont, H. M., P. Hopkins, H. S. Edelson, H. B. Kaplan, R. Ludewig, G. Weissmann, and S. Abramson. 1986. Complement activation during systemic lupus erythematosus: C3a and C5a anaphylatoxins circulate during exacerbations of disease. Arthritis Rheum. 29:1085.
7. Hugli, T. E. 1981. The structural basis for anaphylatoxin and chemotactic functions of C3a, C4a, and C5a. Crit. Rev. Immunol. 1:321.
8. Hugli, T. E. 1989. Structure and function of C3a anaphylatoxin. Curr. Top. Microbiol. Immunol. 153:181.
9. Köhl, J., and D. Bitter-Suermann. 1993. Anaphylatoxins. In Complement in Health and Disease. K. Whaley, M. Loos, and J. M. Weiler, eds. Kluwer Academic Publishers Group, Lancaster, U.K., p. 299.
10. Goldstein, I. M. 1992. Complement: biologically active products. In inflammation: Basic Principles and Clinical Correlates. J. I. Gallin, I. M. Goldstein, and R. Snyderman, eds. Raven Press, New York, p. 63.
11. Goodman, M. G., D. E. Chenoweth, and W. O. Weigle. 1982. Induction of interleukin-1 secretion and enhancement of humoral immunity by binding of C5a to macrophage surface C5a receptors. J. Exp. Med. 156:912.
12. Scholz, W., M. R. McClurg, G. J. Cardenas, M. Smith, D. J. Noonan, T. E. Hugli, and E. L. Morgan. 1990. C5a-mediated release of interleukin-6 by human monocytes. Clin. Immunol. Immunopathol. 57:297.
13. Schindler, R., J. A. Gelfand, and C. A. Dinarello. 1990. Recombinant C5a stimulates transcription rather than translation of IL-1 and TNF: translational signal provided by LPS or IL-1 itself. Blood 76:1631.
14. Daffern, P. J., P. H. Pfeifer, J. A. Ember, and T. E. Hugli. 1995. C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation. J. Exp. Med. 181:2119.
15. Morgan, E. L. 1987. The role of prostaglandins in C3a-mediated suppression of human in vitro polyclonal antibody responses. Clin. Immunol. Immunopathol. 44:1.
16. desArg: regulation of TNF-alpha and IL-1β synthesis. J. Immunol. 156:3455.
17. Pepys, M. B. 1976. Role of complement in the induction of the immune response. Transplant. Rev. 32:93.
18. Martinelli, G. P., T. Matsuda, H. S. Waks, and A. G. Osler. 1978. Studies on immunosuppression by cobra venom factor. III. On early responses to sheep erythrocytes in C5-deficient mice. J. Immunol. 121:2052.
19. Böttger, E. C., and D. Bitter-Suermann. 1987. Complement and the regulation of humoral immune responses. Immunol. Today 8:261.
20. Morgan, E. L. 1986. Modulation of the immune response by anaphylatoxins. Complement 3:128.
21. Morgan, E. L., M. L. Thoman, W. O. Weigle, and T. E. Hugli. 1983. Anaphylatoxin-mediated regulation of the immune response. II. C5a-mediated enhancement of human humoral and T cell-mediated immune responses. J. Immunol. 130:1257.
22. Morgan, E. L., W. O. Weigle, and T. E. Hugli. 1982. Anaphylatoxin-mediated regulation of the immune response. I. C3a-mediated suppression of human and murine humoral immune responses. J. Exp. Med. 155:1412.
23. + suppressor T cell. J. Immunol. 134:51.
24. Crass, T., U. Raffetseder, U. Martin, M. Grove, A. Klos, J. Köhl, and W. Bautsch. 1996. Expression cloning of the human C3a anaphylatoxin receptor (C3aR) from differentiated U-937 cells. Eur. J. Immunol. 26:1944.
25. Ames, R. S., H. M. Sarau, P. Nuthulaganti, J. J. Foley, C. Ellis, Z. Zeng, K. Su, A. J. Jurewicz, R. P. Hertzberg, D. J. Bergsma, and C. Kumar. 1996. Molecular cloning and characterization of the human anaphylatoxin C3a receptor. J. Biol. Chem. 271:20231.
26. Roglic, A., E. R. Prossnitz, S. L. Cavanagh, Z. Pan, A. Zou, and R. D. Ye. 1996. cDNA cloning of a novel G protein-coupled receptor with a large extracellular loop structure. Biochim. Biophys. Acta 1305:39.
27. Gerard, N. P., and C. Gerard. 1991. The chemotactic receptor for human C5a anaphylatoxin. Nature 349:614.
28. Boulay, F., L. Mery, M. Tardif, L. Brouchon, and P. Vignais. 1991. Expression cloning of a receptor for C5a anaphylatoxin on differentiated HL-60 cells. Biochemistry 30:2993.
29. Fukuoka, Y., A. Yasui, and T. Tachibana. 1991. Active recombinant C3a of human anaphylatoxin produced in Escherichia coli. Biochem. Biophys. Res. Commun. 175::1131.
30. Hugli, T. E., C. Gerard, M. Kawahara, M. E. Scheetz, R. Barton, S. Briggs, G. Koppel, and S. Russell. 1981. Isolation of three separate anaphylatoxins from complement-activated human serum. Mol. Cell. Biochem. 41:59.
31. Luxembourg, A. T., and N. R. Cooper. 1994. T cell-dependent, B cell-activating properties of antibody-coated small latex beads: a new model for B cell activation. J. Immunol. 153:604.
32. Madsen, M., H. E. Johnson, P. Wendelbote Hansen, and S. E. Christiansen. 1980. Isolation of human T and B lymphocytes by E rosette gradient centrifugation: characterization of the isolated subpopulations. J. Immunol. Methods 33:323.
33. Rothermel, A. L., K. M. Gilbert, and W. O. Weigle. 1991. Differential abilities of Th1 and Th2 to induce polyclonal B cell proliferation. Cell. Immunol. 135:1.
34. Buchner, R. R., S. M. Vogen, W. Fischer, M. L. Thoman, S. D. Sanderson, and E. L. Morgan. 1997. Anti-human κ opioid receptor antibodies: characterization of site-directed neutralizing antibodies specific for a peptide κR (33-52) derived from the predicted amino-terminal region of the human kappa receptor. J. Immunol. 158:1670.
35. 125I-C3a binding. Biochemistry 31:11274.
36. Banchereau, J., and F. Rousset. 1992. Human B lymphocytes: phenotype, proliferation, and differentiation. Adv. Immunol. 52:125.
37. Rieckmann, P., J. M. Tuscano, and J. H. Kehrl. 1997. Tumor necrosis factor-α (TNF-α) and interleukin-6 (1L-6) in B-lymphocyte function. Methods Enzymol. 11:128.
38. Horii, Y., A. Muraguchi, S. Suematsu, T. Matsuda, K. Yoshizaki, T. Hirano, and T. Kishimoto. 1988. Regulation of BSF-2/IL-6 production by human mononuclear cells. J. Immunol. 141:1529.
39. Sung, S. J., L. K. L. Jung, J. A. Walters, W. Chen, C. Y. Wang, and S. M. Fu. 1988. Production of tumor necrosis factor/cachectin by human B cell lines and tonsillar B cells. J. Exp. Med. 168:1539.
40. Xia, X., K. H. Lee, S. C. Clark, and Y. S. Choi. 1989. Recombinant interleukin (IL) 2-induced human B cell differentiation is mediated by autocrine IL-6. Eur. J. Immunol. 19:2275.
41. Rieckmann, P., F. D'Alessandro, R. P. Nordan, A. S. Fauci, and J. H. Kehrl. 1991. IL-6 and tumor necrosis factor-α: autocrine and paracrine cytokines involved in B cell function. J. Immunol. 146:3462.
42. Kehrl, J. H., A. Miller, and A. S. Fauci. 1987. Effect of tumor necrosis factor-α on mitogen-activated human B cells. J. Exp. Med. 166:786.
43. Ember, J. A., N. L. Johansen, and T. E. Hugli. 1991. Designing synthetic super-agonist of C3a anaphylatoxin. Biochemistry, 30:3603.
44. Boettger, E. C., S. Metzger, D. Bitter-Suermann, G. Stevenson, S. Kleindienst, and R. Burger. 1986. Impaired humoral immune response in complement C3-deficient guinea pigs: absence of secondary antibody response. Eur. J. Immunol. 16:1231.
45. Fischer, M. B., M. Ma, S. Goerg, X. Zhou, J. Xia, O. Finco, S. Han, G. Kelsoe, R. G. Howard, T. L. Rothstein, E. Kremmer, F. S. Rosen, and M. C. Carroll. 1996. Regulation of the B cell response to T-dependent antigens by classical pathway complement. J. Immunol. 157:549.
46. Heyman, B., E. J. Wiersma, and T. Kinoshita. 1990. In vivo inhibition of the antibody response by a complement receptor-specific monoclonal antibody. J. Exp. Med. 172:665.
47. Hebell, T., J. M. Ahearn, and D. T. Fearon. 1991. Suppression of the immune response by a soluble complement receptor of B lymphocytes. Science 254:102.
48. Dempsey, P. W., M. E. D. Allison, S. Akkaraju, C. C. Goodnow, D. T. Fearon. 1996. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271:148.
49. O'Garra, A., G. Stapleton, V. Dhar, M. Pearce, J. Schumacher, H. Rugo, D. Barbis, A. Stall, J. Cupp, K. Moore, P. Vieira, T. Mosmann, A. Whitmore, L. Arnold, G. Haughton, and M. Howard. 1990. Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin-10. Int. Immunol. 2:821.
50. Matthes, T., C. Werner-Favre, H. Tang, X. Zhang, V. Kindler, and R. H. Zubler. 1993. Cytokine mRNA expression during an in vitro response of human B lymphocytes: kinetics of B cell tumor necrosis factor alpha, interleukin (IL)6, IL-10, and transforming growth factor β1 mRNAs. J. Exp. Med. 178:521.
51. Baumann, M. A., and C. C. Paul. 1997. Interleukin-5 and human B-lymphocytes. Methods 11:88.
52. Sartori, A., X. Ma, G. Gri, L. Showe, D. Benjamin, and G. Trinchieri. 1997. Interleukin-12: an immunomodulatory cytokine produced by B cells and antigen-presenting cells. Methods 11:116.
53. Burdin, N., C. van Kooten, L. Galibert, J. S. Abrams, J. Wijdenes, J. Banchereau, and F. Rousset. 1995. Endogenous 1L-6 and IL-10 contribute to the differentiation of CD40-activated human B lymphocytes. J. Immunol. 154:2533.
54. Kretschmar, T., A. Jeromin, C. Gietz, W. Bautsch, A. Klos, J. Köhl, G. Rechkemmer, and D. Bitter-Suermann. 1993. Chronic myelogenous leukemia-derived basophilic granulocytes express a functional active receptor for the anaphylatoxin C3a. Eur. J. Immunol. 23:558.
55. Goers, J. W., M. M. Glovsky, M. W. Hunkapiller, V. Fransworth, and J. H. Richards. 1984. Studies on C3ahu binding to human eosinophils: characterization of binding. Int. Arch Allergy Appl. Immun. 74:147.
56. Fukuoka, Y., and T. E. Hugli. 1988. Demonstration of a specific C3a receptor on guinea pig platelets. J. Immunol. 140:3496.
57. Bokisch, V. A., and H. J. Müller-Eberhard. 1970. Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J. Clin. Invest. 49:2427.
58. Charriaut, C., A. Senik, J.-P. Kolb, M. Barel, and R. Frade. 1982. Inhibition of in vitro natural killer activity by the third component of complement: role for the C3a fragment. Proc. Natl Acad. Sci. USA 79:6003.
59. Mousli, M., T. E. Hugli, Y. Landry, and C. Bronner. 1992. A mechanism of action for anaphylatoxin C3a stimulation of mast cells. J. Immunol. 148:2456.